Michael Beckloff joined Azurity Pharmaceuticals (formerly Silvergate Pharmaceuticals, Inc.) as Co-Founder of Silvergate and Chief Development Officer in 2010. Mike has 35 years of experience in the pharmaceutical, biologics and medical device industries, with a focus on product development and regulatory sciences. His company, Beckloff Associates, a preeminent global consulting group, employed over 100 pharmaceutical and regulatory scientists, providing service to over 200 clients worldwide. He has worked on numerous approved NDAs, ANDA, and MAAs.
Cardinal Health acquired Beckloff Associates in 2004 where Mike continued until transitioning to Silvergate Pharmaceuticals as Chief Development officer with a focus on developing and delivering high quality pediatric drug products. Mike is responsible for all R&D functions, including new product development and approval, and his team of highly skilled drug development professionals has been responsible for guiding the development of all of Silvergate products, resulting in four approved and commercial NDA drug products.
Mike received his Cellular Biology Degree from the University of Kansas.
Azurity Pharmaceuticals™, Inc. was formerly known as CutisPharma®, Inc. Product packaging may reflect either name.
All product imagery is for representation purposes only - not actual labels.
© 2020 Azurity Pharmaceuticals™, Inc. All Rights Reserved.